{"nctId":"NCT02040844","briefTitle":"Phase III Cat-PAD Follow-on Study","startDateStruct":{"date":"2014-02","type":"ACTUAL"},"conditions":["Cat Allergy"],"count":430,"armGroups":[{"label":"Cat-PAD Treatment 1","type":"OTHER","interventionNames":["Drug: Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]"]},{"label":"Cat-PAD Treatment 2","type":"OTHER","interventionNames":["Drug: Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]"]},{"label":"Cat-PAD Treatment 3","type":"OTHER","interventionNames":["Drug: Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]"]}],"interventions":[{"name":"Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]","otherNames":[]},{"name":"Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]","otherNames":[]},{"name":"Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* previously completed clinical study CP007 \\[NCT01620762\\]\n\nExclusion Criteria:\n\n* started allergen therapy since completing CP007\n* Institutionalised due to a legal or regulatory order","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Combined Score (CS) Consisting of TRSS/8+Allergy Medication Score[AMS])","description":"The primary endpoint was the mean Combined Score (CS) in Cat-PAD treatment groups compared with the mean CS in the placebo group. This was assessed one year after completing the original study (CP007).\n\nCS = Total Rhinoconjunctivitis Symptom Score (TRSS) + Allergy Medication Score (AMS). Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose and itchy nose and 4 ocular symptoms: itchy eyes; watery eyes; red eyes and sore eyes. Each symptom was rated in severity on a score of 0-3 (0=absent, 3=severe) and the TRSS was divided by the number of symptoms to provide an average score per symptom of 0-3.\n\nAMS was scored from 0 (no allergy rescue medication use per day) to 3 (at least one dose of systemic corticosteroid per day). The AMS score was not additive, and therefore the maximum AMS was 3 and the maximum CS was 6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":"0.16"},{"groupId":"OG001","value":"1.91","spread":"0.15"},{"groupId":"OG002","value":"1.93","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Mean TRSS","description":"Mean Total Rhinoconjunctivitis Symptom Score (TRSS) in Cat-PAD treatment groups compared with placebo.\n\nEight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose, and itchy nose and 4 ocular symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome), therefore TRSS could range from 0 to 24. Higher TRSS reflected more severe symptom scores. Symptoms were scored daily for a period of approximately 3 weeks one year after completing the first study (CP007).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.95","spread":"0.69"},{"groupId":"OG001","value":"13.15","spread":"0.66"},{"groupId":"OG002","value":"12.92","spread":"0.67"}]}]}]},{"type":"SECONDARY","title":"Mean Component Scores of the TRSS (Nasal)","description":"TNSS (Total nasal symptom score) was the sum of all the nasal symptom scores (runny nose; sneezing; blocked nose; itchy nose) and could range from 0 to 12. Higher TNSS reflected more severe symptoms.\n\nSubjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks 1 year after completing the original CP007 study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.06","spread":"0.39"},{"groupId":"OG001","value":"7.17","spread":"0.37"},{"groupId":"OG002","value":"6.96","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Mean Component Scores of the TRSS (Ocular)","description":"Mean daily Total Ocular Symptom Score (TOSS) in Cat-PAD treatment groups compared to placebo groups\n\nEight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose, and itchy nose and 4 ocular symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. TOSS was the sum of all the ocular symptom scores (itchy eyes; watery eyes; red eyes; sore eyes) and could range from 0 to 12. Higher TOSS reflected more severe symptoms.\n\nSubjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks one year after completing the original CP007 study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.90","spread":"0.35"},{"groupId":"OG001","value":"5.97","spread":"0.33"},{"groupId":"OG002","value":"6.00","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Mean Allergy Medication Score (AMS)","description":"Mean AMS (Allergy medication score) in Cat-PAD treatment groups compared with placebo groups.\n\nThe use of rhinoconjunctivitis rescue medications was recorded by the subject for a period of 21 days, on a daily basis just before bedtime, approximately 1 year after completing the original CP007 study. Rescue medication use was scored based on a previously published system as follows: 0 = no allergy rescue medication used per day; 0.5 = at least one dose of antihistamine eye drops used per day; 1 = at least one dose of oral antihistamine used per day; 2 = at least one dose of intranasal corticosteroid used per day; 3 = at least one dose of systemic corticosteroid used per day. The score was according to the highest level of rescue medication used and was not additive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":"0.09"},{"groupId":"OG001","value":"0.27","spread":"0.09"},{"groupId":"OG002","value":"0.31","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Mean RQLQ Score","description":"The RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire) was completed by subjects one year after the completion of the previous study (CP007).\n\nThe RQLQ is a validated method of assessing quality of life and has 28 questions in seven domains (activity limitation, sleep problems, nasal symptoms, eye symptoms, non-nasal/eye symptoms, practical problems and emotional function). Subjects recalled how their rhinoconjunctivitis had been during the last week and responded to each question on a seven-point scale (0 = no impairment, 6 = maximum impairment). The questions were equally weighted, and the RQLQ score was the mean of the 28 questions and could range from zero to six.\n\nA higher score indicated greater impact on quality of life and thus a low score indicated a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.58","spread":"0.22"},{"groupId":"OG001","value":"1.62","spread":"0.21"},{"groupId":"OG002","value":"1.51","spread":"0.22"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":138},"commonTop":["Nasopharyngitis","Sinusitis","Headache","Influenza","Upper respiratory tract infection"]}}}